Fractyl Health (GUTS) Share-based Compensation (2023 - 2026)
Fractyl Health (GUTS) reported Share-based Compensation of $2.5 million for Q1 2026, up 80.01% year-on-year from $1.4 million in Q1 2025, and up 36.44% quarter-over-quarter from $1.9 million in Q4 2025.
Fractyl Health (GUTS) has 4 years of Share-based Compensation data on file, last reported at $2.5 million in Q1 2026.
- For the quarter ending Q1 2026, Share-based Compensation rose 80.01% year-over-year to $2.5 million; the trailing twelve-month figure through Mar 2026 stood at $7.8 million (down 26.43% YoY), and the FY2025 full-year result was $6.7 million, down 53.67% from the prior year.
- Share-based Compensation for Q1 2026 stood at $2.5 million, up from $1.9 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $5.2 million in Q1 2024 and bottomed at $857000.0 in Q1 2023.
- A 4-year average of $2.1 million and a median of $1.8 million in 2025 frame the typical range for Share-based Compensation.
- Across the five-year window, Share-based Compensation surged 508.75% in 2024 and sank 73.05% in 2025, its largest moves.
- Tracing GUTS's Share-based Compensation over 4 years: stood at $1.3 million in 2023, then jumped by 127.19% to $2.9 million in 2024, then tumbled by 36.01% to $1.9 million in 2025, then jumped by 36.44% to $2.5 million in 2026.
- According to Business Quant data, Share-based Compensation over the past three periods registered $2.5 million, $1.9 million, and $1.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,638,563.89 Bn | 1,638,563.89 Bn | - | 892,057.00 |
| 2 | Alterity Therapeutics | 767,934.24 Bn | 767,934.20 Bn | - | - |
| 3 | Legend Biotech | 2,937.00 Bn | 2,936.10 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 2,169.69 Bn | 2,169.69 Bn | - | 305,000.00 |
| 6 | Vertex Pharmaceuticals | 110.41 Bn | 103.16 Bn | 2.59 Bn | 166.40 Mn |
| 7 | Regeneron Pharmaceuticals | 66.44 Bn | 57.69 Bn | 3.31 Bn | 257.40 Mn |
| 8 | Evaxion A | 65.44 Bn | 65.42 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.53 Bn | 36.52 Bn | 959.66 Mn | 70.15 Mn |
| 10 | Fractyl Health | 19.24 Mn | 19.24 Mn | - | 2.53 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.53 Mn |
| Mar 31, 2026 | 2.53 Mn |
| Dec 31, 2025 | 1.86 Mn |
| Dec 31, 2025 | 1.86 Mn |
| Sep 30, 2025 | 1.64 Mn |
| Sep 30, 2025 | 1.64 Mn |
| Jun 30, 2025 | 1.79 Mn |
| Jun 30, 2025 | 1.79 Mn |
| Mar 31, 2025 | 1.41 Mn |
| Mar 31, 2025 | 1.41 Mn |
| Dec 31, 2024 | 2.90 Mn |
| Dec 31, 2024 | 2.90 Mn |
| Sep 30, 2024 | 2.52 Mn |
| Sep 30, 2024 | 2.52 Mn |
| Jun 30, 2024 | 3.79 Mn |
| Jun 30, 2024 | 3.79 Mn |
| Mar 31, 2024 | 5.22 Mn |
| Mar 31, 2024 | 5.22 Mn |
| Dec 31, 2023 | 1.28 Mn |
| Dec 31, 2023 | 1.28 Mn |
| Sep 30, 2023 | 1.09 Mn |
| Sep 30, 2023 | 1.09 Mn |
| Jun 30, 2023 | 1.07 Mn |
| Jun 30, 2023 | 1.07 Mn |
| Mar 31, 2023 | 857,000.00 |
| Mar 31, 2023 | 857,000.00 |